Zura Bio (NASDAQ:ZURA) Stock Price Up 0.3% – Time to Buy?

Zura Bio Limited (NASDAQ:ZURA)’s share price rose 0.3% on Monday . The stock traded as high as $6.57 and last traded at $6.38. Approximately 464,254 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 970,103 shares. The stock had previously closed at $6.36.

Analyst Ratings Changes

Several research firms have recently issued reports on ZURA. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Zura Bio in a research note on Friday, November 14th. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Stock Up 0.3%

The firm has a market cap of $414.83 million, a price-to-earnings ratio of -9.82 and a beta of 0.20. The firm has a fifty day moving average price of $4.55 and a 200-day moving average price of $3.28.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Equities research analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently bought and sold shares of ZURA. Suvretta Capital Management LLC increased its position in Zura Bio by 12.6% during the third quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock worth $23,698,000 after purchasing an additional 611,952 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,052,732 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Zura Bio by 1.6% during the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock valued at $6,755,000 after buying an additional 24,000 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Zura Bio during the 3rd quarter valued at $3,568,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Zura Bio during the 3rd quarter worth $2,165,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.